This trial will compare a new drug to chemo to treat ovarian, peritoneal, and fallopian tube cancer that has not responded to platinum therapy.
- Ovarian Neoplasms
2 Primary · 11 Secondary · Reporting Duration: Up to 2 years
3 Treatment Groups
Arm B: MORAb-202 Dose 2
1 of 3
Arm A: MORAb-202 Dose 1
1 of 3
Arm C: Investigator's Choice Chemotherapy
1 of 3
150 Total Participants · 3 Treatment Groups
Primary Treatment: Arm B: MORAb-202 Dose 2 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Female Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many locales are managing this trial?
"This trial is enrolling participants from Spectrum Health Hospitals in Grand Rapids, Michigan, UF Health Endoscopy Center in Gainesville, Florida, and Providence Sacred Heart Medical Centre and Children's Hospital in Spokane Washington; additionally there are 12 other medical centres taking part." - Anonymous Online Contributor
Is the research team actively searching for participants to join this endeavor?
"As reported on clinicaltrials.gov, this research project is not presently accepting new participants; it was originally posted in November 11th 2022 and last revised four days later. Despite this study's current lack of recruitment proceedings, 545 other medical studies are actively enrolling patients at present." - Anonymous Online Contributor
Has the United States Food and Drug Administration (FDA) approved MORAb-202 Dose 1 in Arm A?
"As this trial is in Phase 2, there are some safety-related data available but no evidence to support efficacy. Thus our team at Power assigned a score of two on the scale from one to three for MORAb-202 Dose 1's safety rating." - Anonymous Online Contributor